TinyGemsBreaks Archive - Page 45 of 125

WednesdayOct 25, 2023 10:46 am

TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Enters Agreements for Private Placement, Preferred Investment Options

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, has entered into a definitive agreement for the issue and sale of more than 3 million common shares, or prefunded warrants in lieu thereof. Specifically, the company agreed to a private placement of 3,012,049 common shares priced at $0.83 per share. In addition, the company entered an agreement for an associated preferred investment option as well as a definitive agreement regarding specific outstanding preferred investment options issued in November 2022. The announcement outlines specifics of the agreement. The company also…

TuesdayOct 24, 2023 12:20 pm

TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Advance INM-901 Following Positive Proof-of-Concept Results

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced its selection of a lead Alzheimer’s disease drug candidate, named INM-901, following positive results from several proof-of-concept studies in a validated Alzheimer’s treatment model. InMed will be advancing cannabinoid analog INM-901 in its pharmaceutical drug development program. “The most recent studies of INM-901 demonstrate promising disease-modifying effects in an Alzheimer’s disease treatment model,” said Dr. Eric Hsu, InMed’s SVP of preclinical research and development. “We are optimistic that the next stage of studies will continue to show how…

TuesdayOct 24, 2023 11:42 am

TinyGemsBreaks – GEMXX Corporation (GEMZ) Releases Gold Production Report for BC-Based Snow Creek Test Mine Site

GEMXX (OTC: GEMZ), a leader in the ammolite gemstone mine-to-market segment and a 50% partner in Canadian gold-exploration company Crazy Horse Mining Inc. (“CHMI”), has successfully completed its third and final clean-out and recording of gold production at the Snow Creek Mine site for the 2023 mining season. According to the announcement, GEMXX and CHMI have processed 31,200 cubic yards of gold-bearing ore during the 2023 test season; those results met all expectations, the report noted, and are positive considering much of the material used during the test program was surface “gold bearing ore” that had been stockpiled when making…

MondayOct 23, 2023 11:12 am

TinyGemsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Releases Update on Progress of Action Filed Against Key Broker Dealers

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, is reporting on the status of the lawsuit it filed against TD Ameritrade, Charles Schwab, National Finance Services and others alleging that those broker dealers engaged in a scheme to manipulate the share price of the company’s securities. Mullen filed the lawsuit in August 2023 in the United States District Court in the Southern District of New York. The company is seeking compensatory damages and injunctive relief from the defendants “unlawful conduct in violation of Section 10b and Rule 10b-5 promulgated thereunder of the Securities Exchange Act of 1934.” Earlier…

FridayOct 20, 2023 3:37 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Committed to R&D, Eyeing Excellent Opportunities

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator seeking to enhance the bioavailability of multiple active pharmaceutical ingredients using its patented DehydraTECH(TM) drug delivery technology platform. The company continues to devote an increasing proportion of its resources and focus toward research and development (“R&D”) as part of its overall goal to establish areas of investigation for commercial pursuits and reduce risks of the unknown for both commercial and regulatory endeavors. “In the three months ended May 31, 2023 (‘Q3 2023’), for example, the company increased its R&D expenses 118% year over year to $1.64 million from $752,095 in Q3…

FridayOct 20, 2023 2:52 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advancing Drive Toward Potential New GBM Treatment

CNS Pharmaceuticals (NASDAQ: CNSP) recently announced rapid enrollment in its potentially pivotal study involving its flagship drug candidate, Berubicin, and is moving closer to reporting the results of its drive toward a new treatment for the effectively incurable brain cancer glioblastoma (“GBM”). “The Texas-based company has clinical trial sites operating in the U.S., Italy, France, Spain, and Switzerland, to evaluate Berubicin’s performance against standard of care alkylating chemotherapy agent Lomustine for treating recurrent GBM. GBM has been generally untreatable by anthracyclines because of their inability to cross the blood-brain barrier, but Berubicin is believed to be able to cross the…

FridayOct 20, 2023 12:02 pm

TinyGemsBreaks — Cepton Inc. (NASDAQ: CPTN) CEO Featured in Latest Proactive Segment

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, is in the spotlight. Cepton cofounder and CEO Dr. Jun Pei is the featured guest on the latest release from Proactive. During the segment, Pei and Proactive host Steve Darling discussed the connection between LiDAR technology and eye safety, with Pei explaining how LIDAR can protect eyes. Pei also summarized how Cepton’s processes and approach ensures safety standards are met. During his comments, Pei observed that all devices placed on vehicles must meet regulatory eye safety standards and explained misconceptions about the impact of different wavelengths on safety;…

ThursdayOct 19, 2023 3:01 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Announces Participation at Upcoming Virtual Investor Ask the CEO Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured at this month’s Virtual Investor Ask the CEO Conference. CNS Pharmaceuticals CEO John Climaco is scheduled to participate in a live moderated webcast during the conference; the webcast is slated to start at 4 p.m. ET. The distinctive conference provides a unique opportunity for members of the investment community to ask questions directly to leaders of specific companies during the live event. According to the announcement, executive answer as many questions…

ThursdayOct 19, 2023 12:49 pm

TinyGemsBreaks — Cepton Inc. (NASDAQ: CPTN) Schedules Q3 Earnings Release, Conference Call Date

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, is planning to release its third-quarter 2023 financial results on Nov. 9, 2023; the report will be released following market close. Cepton has also scheduled a conference call and webcast for that same day; the call will begin 5:30 p.m. ET. During the call, management will discuss the quarter earnings report as well as provide a business update. The call can be accessed by dialing 1-877-300-8521 (toll free) or 1-412-317-6026 for international callers. According to the announcement, a replay of the conference call will be available approximately three…

ThursdayOct 19, 2023 12:19 pm

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Announces Filing of Preliminary Proxy Statement

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced that it has filed a preliminary proxy statement with the Securities and Exchange Commission (the “SEC”) regarding a special stockholders’ meeting to be held on Dec. 15, 2023, to authorize Mullen’s board of directors to effect a reverse stock split of the company’s common stock at an exchange ratio between 1-for-2 to 1-for-100. Mullen expects that the board’s primary focus in determining whether or not to effectuate the reverse stock split will be the ability to obtain and maintain a continued price of at least $1.00 per share…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

TinyGemsBreaks